Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers
- PMID: 38815248
- DOI: 10.1021/jacs.3c06483
Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers
Abstract
Aberrant DNA repair is a hallmark of cancer, and many tumors display reduced DNA repair capacities that sensitize them to genotoxins. Here, we demonstrate that the differential DNA repair capacities of healthy and transformed tissue may be exploited to obtain highly selective chemotherapies. We show that the novel N3-(2-fluoroethyl)imidazotetrazine "KL-50" is a selective toxin toward tumors that lack the DNA repair protein O6-methylguanine-DNA-methyltransferase (MGMT), which reverses the formation of O6-alkylguanine lesions. We establish that KL-50 generates DNA interstrand cross-links (ICLs) by a multistep process comprising DNA alkylation to generate an O6-(2-fluoroethyl)guanine (O6FEtG) lesion, slow unimolecular displacement of fluoride to form an N1,O6-ethanoguanine (N1,O6EtG) intermediate, and ring-opening by the adjacent cytidine. The slow rate of N1,O6EtG formation allows healthy cells expressing MGMT to reverse the initial O6FEtG lesion before it evolves to N1,O6EtG, thereby suppressing the formation of toxic DNA-MGMT cross-links and reducing the amount of DNA ICLs generated in healthy cells. In contrast, O6-(2-chloroethyl)guanine lesions produced by agents such as lomustine and the N3-(2-chloroethyl)imidazotetrazine mitozolomide rapidly evolve to N1,O6EtG, resulting in the formation of DNA-MGMT cross-links and DNA ICLs in healthy tissue. These studies suggest that careful consideration of the rates of chemical DNA modification and biochemical DNA repair may lead to the identification of other tumor-specific genotoxic agents.
Similar articles
-
Mechanism of AGT-Mediated Repair of dG-dC Cross-Links in the Drug Resistance to Chloroethylnitrosoureas: Molecular Docking, MD Simulation, and ONIOM (QM/MM) Investigation.J Chem Inf Model. 2024 Apr 22;64(8):3411-3429. doi: 10.1021/acs.jcim.3c01958. Epub 2024 Mar 21. J Chem Inf Model. 2024. PMID: 38511939
-
Posttranslational Regulation of O(6)-Methylguanine-DNA Methyltransferase (MGMT) and New Opportunities for Treatment of Brain Cancers.Mini Rev Med Chem. 2016;16(6):455-64. doi: 10.2174/1389557515666150722101046. Mini Rev Med Chem. 2016. PMID: 26202203 Review.
-
Tumor-associated mutations in O��� -methylguanine DNA-methyltransferase (MGMT) reduce DNA repair functionality.Mol Carcinog. 2014 Mar;53(3):201-10. doi: 10.1002/mc.21964. Epub 2012 Oct 12. Mol Carcinog. 2014. PMID: 23065697 Free PMC article.
-
Glycolytic inhibition by 3-bromopyruvate increases the cytotoxic effects of chloroethylnitrosoureas to human glioma cells and the DNA interstrand cross-links formation.Toxicology. 2020 Apr 15;435:152413. doi: 10.1016/j.tox.2020.152413. Epub 2020 Feb 25. Toxicology. 2020. PMID: 32109525
-
The specific role of O6-methylguanine-DNA methyltransferase inhibitors in cancer chemotherapy.Future Med Chem. 2018 Aug 1;10(16):1971-1996. doi: 10.4155/fmc-2018-0069. Epub 2018 Jul 13. Future Med Chem. 2018. PMID: 30001630 Review.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials